Patent ID: 11939381
Assignee: ELI LILLY AND COMPANY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An antibody that antagonizes human PD-1 (SEQ ID NO:25) and agonizes human CD137 (SEQ ID NO:26), comprising a first and second heavy chain and a first and second light chain, wherein each chain comprises a variable region and a constant region, and wherein:
a) the first heavy chain of the antibody comprises a complementarity-determining region 1 (CDR1) having the amino acid sequence of SEQ ID NO:1, a complementarity-determining region 2 (CDR2) having the amino acid sequence of SEQ ID NO:2, and a complementarity-determining region (CDR3) having the amino acid sequence of SEQ ID NO:3;
b) the first light chain of the antibody comprises a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:8, and a CDR3 having the amino acid sequence of SEQ ID NO:9;
c) the second heavy chain of the antibody comprises a CDR1 having the amino acid sequence of SEQ ID NO:13, a CDR2 having the amino acid sequence of SEQ ID NO:14, and a CDR3 having the amino acid sequence of SEQ ID NO:15; and
d) the second light chain of the antibody comprises a CDR1 having the amino acid sequence of SEQ ID NO:19, a CDR2 having the amino acid sequence of SEQ ID NO:20, and a CDR3 having the amino acid sequence of SEQ ID NO:21.